ImmunityBio Inc. Watch

from 10-Q 68 pages Certain Information Has Been Redacted From This Exhibit in Accordance With Item 601(b)(10)(iv) of Regulation S-K Because Such Information (I) Is Not Material and (II) Is the Type of Information the Registrant Treats as Private or Confidential. Information That Has Been So Redacted From This Exhibit Has Been Marked With “[*****]” to Indicate the Omission. Settlement Agreement and Release

from 10-Q 15 pages Immunitybio, Inc. 2015 Equity Incentive Plan

from 10-Q 15 pages Immunitybio, Inc. 2015 Equity Incentive Plan

from 10-K 1 page October 3, 2023 Duley Road, LLC 9922 Jefferson Boulevard Culver City, Ca 90232 Attn: Charles N. Kenworthy Re: Building #3 at 400 Duley Road Dear Mr. Kenworthy

from 10-K 10 pages Immunitybio, Inc. Amended and Restated Promissory Note

from 10-K 17 pages Stock Purchase and Option Agreement

from 10-K 31 pages Security and Pledge Agreement

from 10-K 86 pages [Certain Information in This Exhibit Identified by [*****] Is Confidential and Has Been Excluded Because the Registrant Actually Treats That Information as Confidential] Revenue Interest Purchase Agreement Dated as of December 29, 2023 Among Immunitybio, Inc., as the Company, the Purchasers From Time to Time Party Hereto and Infinity SA LLC, as Purchaser Agent

from 10-Q 3 pages Reference Is Made to the Promissory Note Issued by Immunitybio, Inc., a Delaware Corporation (The “Company”) to Nant Capital, LLC, a Delaware Limited Liability Company (The “Holder”) Dated June 13, 2023 in the Stated Principal Amount of $30,000,000 (As Amended From Time to Time, the “Note”). Capitalized Terms Used but Not Defined Herein Are Used as Defined in the Note. This Letter Amendment Confirms Our Mutual Agreement That: 1.the First Paragraph of the Note Is Hereby Amended by Replacing the Phrase “December 31, 2023 (The “Maturity Date”)” Therein With the Phrase “December 31, 2024 (The “Maturity Date”)”. Except as Expressly Set Forth Herein, the Provisions of the Note Shall Remain Unchanged and in Full Force and Effect and the Parties Hereto Hereby Ratify and Reaffirm Each and Every Term, Covenant and Condition Set Forth in the Note as of the Date Hereof, as Amended by This Letter Amendment. This Letter Amendment Shall Be Governed by the Law of the State of California (Without Giving Effect to the Conflict of Law Principles That Would Result in the Application of the Law of a Different Jurisdiction)

from 10-Q 3 pages Reference Is Made to the Convertible Promissory Note Issued by Immunitybio, Inc., a Delaware Corporation (The “Company”) to Nant Capital, LLC, a Delaware Limited Liability Company (The “Holder”) Dated March 31, 2023 in the Stated Principal Amount of $30,000,000 (As Amended From Time to Time, the “Note”). Capitalized Terms Used but Not Defined Herein Are Used as Defined in the Note. This Letter Amendment Confirms Our Mutual Agreement That: 1.the First Paragraph of the Note Is Hereby Amended by Replacing the Phrase “December 31, 2023 (The “Maturity Date”)” Therein With the Phrase “December 31, 2024 (The “Maturity Date”)”. Except as Expressly Set Forth Herein, the Provisions of the Note Shall Remain Unchanged and in Full Force and Effect and the Parties Hereto Hereby Ratify and Reaffirm Each and Every Term, Covenant and Condition Set Forth in the Note as of the Date Hereof, as Amended by This Letter Amendment. This Letter Amendment Shall Be Governed by the Law of the State of California (Without Giving Effect to the Conflict of Law Principles That Would Result in the Application of the Law of a Different Jurisdiction)

from 10-Q 3 pages Reference Is Made to the Promissory Note Issued by Immunitybio, Inc., a Delaware Corporation (The “Company”) to Nant Capital, LLC, a Delaware Limited Liability Company (The “Holder”) Dated December 12, 2022 in the Stated Principal Amount of $50,000,000 (As Amended From Time to Time, the “Note”). Capitalized Terms Used but Not Defined Herein Are Used as Defined in the Note. This Letter Amendment Confirms Our Mutual Agreement That: 1.the First Paragraph of the Note Is Hereby Amended by Replacing the Phrase “December 31, 2023 (The “Maturity Date”)” Therein With the Phrase “December 31, 2024 (The “Maturity Date”)”. Except as Expressly Set Forth Herein, the Provisions of the Note Shall Remain Unchanged and in Full Force and Effect and the Parties Hereto Hereby Ratify and Reaffirm Each and Every Term, Covenant and Condition Set Forth in the Note as of the Date Hereof, as Amended by This Letter Amendment. This Letter Amendment Shall Be Governed by the Law of the State of California (Without Giving Effect to the Conflict of Law Principles That Would Result in the Application of the Law of a Different Jurisdiction)

from 10-Q 3 pages Reference Is Made to the Promissory Note Issued by Immunitybio, Inc., a Delaware Corporation (The “Company”) to Nant Capital, LLC, a Delaware Limited Liability Company (The “Holder”) Dated August 31, 2022 in the Stated Principal Amount of $125,000,000 (As Amended From Time to Time, the “Note”). Capitalized Terms Used but Not Defined Herein Are Used as Defined in the Note. This Letter Amendment Confirms Our Mutual Agreement That: 1.the First Paragraph of the Note Is Hereby Amended by Replacing the Phrase “December 31, 2023 (The “Maturity Date”)” Therein With the Phrase “December 31, 2024 (The “Maturity Date”)”. Except as Expressly Set Forth Herein, the Provisions of the Note Shall Remain Unchanged and in Full Force and Effect and the Parties Hereto Hereby Ratify and Reaffirm Each and Every Term, Covenant and Condition Set Forth in the Note as of the Date Hereof, as Amended by This Letter Amendment. This Letter Amendment Shall Be Governed by the Law of the State of California (Without Giving Effect to the Conflict of Law Principles That Would Result in the Application of the Law of a Different Jurisdiction)

from 10-Q 3 pages Reference Is Made to the Amended and Restated Promissory Note Issued by Immunitybio, Inc., a Delaware Corporation (The “Company”) to Nant Capital, LLC, a Delaware Limited Liability Company (The “Holder”) Dated August 31, 2022 in the Stated Principal Amount of $300,000,000 (As Amended From Time to Time, the “Note”). Capitalized Terms Used but Not Defined Herein Are Used as Defined in the Note. This Letter Amendment Confirms Our Mutual Agreement That: 1.the First Paragraph of the Note Is Hereby Amended by Replacing the Phrase “December 31, 2023 (The “Maturity Date”)” Therein With the Phrase “December 31, 2024 (The “Maturity Date”)”. Except as Expressly Set Forth Herein, the Provisions of the Note Shall Remain Unchanged and in Full Force and Effect and the Parties Hereto Hereby Ratify and Reaffirm Each and Every Term, Covenant and Condition Set Forth in the Note as of the Date Hereof, as Amended by This Letter Amendment. This Letter Amendment Shall Be Governed by the Law of the State of California (Without Giving Effect to the Conflict of Law Principles That Would Result in the Application of the Law of a Different Jurisdiction)

from 10-Q 7 pages Immunitybio, Inc. Convertible Promissory Note

from 10-Q 9 pages Stock Purchase Agreement

from 10-Q 4 pages Lease Termination Agreement

from 10-Q 1 page June 30, 2023 605 Doug St., LLC 2040 E. Mariposa Ave. El Segundo, Ca 90245 to Whom It May Concern

from 8-K 39 pages Securities Purchase Agreement

from 8-K 7 pages Immunitybio, Inc. Promissory Note

from 8-K 7 pages Immunitybio, Inc. Convertible Promissory Note